• Product nameAnti-TACI antibody [1A1]
    See all TACI primary antibodies
  • Description
    Rat monoclonal [1A1] to TACI
  • Tested applicationsSuitable for: Flow Cytmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Tissue/ cell preparation (Human) - human TACI transfected into rat RBL cells.

  • Positive control
    • Blood B cells.



Our Abpromise guarantee covers the use of ab16230 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use a concentration of 5 µg/ml. Levels or Taci are variable and often low in human blood.

ab18450-Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.


  • FunctionReceptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity.
  • Tissue specificityHighly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells.
  • Involvement in diseaseDefects in TNFRSF13B are the cause of immunodeficiency common variable type 2 (CVID2) [MIM:240500]. CVID2 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
    Defects in TNFRSF13B are a cause of immunoglobulin A deficiency 2 (IGAD2) [MIM:609529]. Selective deficiency of immunoglobulin A (IGAD) is the most common form of primary immunodeficiency, with an incidence of approximately 1 in 600 individuals in the western world. Individuals with symptomatic IGAD often have deficiency of IgG subclasses or decreased antibody response to carbohydrate antigens such as pneumococcal polysaccharide vaccine. Individuals with IGAD also suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. In vitro studies have suggested that some individuals with IGAD have impaired isotype class switching to IgA and others may have a post-switch defect. IGAD and CVID have been known to coexist in families. Some individuals initially present with IGAD1 and then develop CVID. These observations suggest that some cases of IGAD and CVID may have a common etiology.
  • Sequence similaritiesContains 2 TNFR-Cys repeats.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • CD 267 antibody
    • CD267 antibody
    • CD267 antigen antibody
    • CVID antibody
    • CVID2 antibody
    • FLJ39942 antibody
    • MGC133214 antibody
    • MGC39952 antibody
    • OTTHUMP00000065442 antibody
    • TNFRSF 13B antibody
    • TNFRSF 14B antibody
    • TNFRSF13B antibody
    • TNFRSF13B protein antibody
    • TNFRSF14B antibody
    • TR13B_HUMAN antibody
    • Transmembrane activator and CAML interactor antibody
    • Tumor necrosis factor receptor 13B antibody
    • Tumor necrosis factor receptor superfamily member 13B antibody
    see all

References for Anti-TACI antibody [1A1] (ab16230)

This product has been referenced in:
  • Schwaller J  et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 109:331-8 (2007). Read more (PubMed: 17190854) »
  • Salzer U  et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 37:820-8 (2005). Read more (PubMed: 16007087) »

See all 3 Publications for this product

Product Wall

Thank you for your enquiry. According to our records there were some quality issues around this time that led to the removal of various applications although the application of FACS by this antibody was not questioned. However, I am prepared to o...

Read More

I'm sorry to hear the customer is experiencing problems in FACS with some of our antibodies, it is likely that the problem is protocol related. I have received this morning a detailed FACS protocol with details of the buffers to use and fixative to use...

Read More